Propyl coenzyme A | 70019-69-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - S-烷基辅酶A
• 英文名称: Propyl coenzyme A
• 英文别名: [[5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [3-hydroxy-2,2-dimethyl-4-oxo-4-[[3-oxo-3-(2-propan-2-ylsulfanylethylamino)propyl]amino]butyl] hydrogen phosphate
• CAS: 70019-69-1
• 化学式: C₂₄H₄₂N₇O₁₆P₃S
• 分子量: 809.6
• InChiKey: QOSXFJDDUVQOJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.6
• 重原子数：
  51
• 可旋转键数：
  20
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  372
• 氢给体数：
  9
• 氢受体数：
  21

文献信息

• Cytotoxic peptides and conjugates thereof
  申请人：NOVARTIS AG

  公开号：US10787480B2

  公开（公告）日：2020-09-29

  Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

  本文公开了如本文所述的式 (I) 的新型细胞毒性肽： 以及使用这种肽制造免疫结合剂（即抗体药物结合剂）的方法 本发明还描述了免疫结合剂（即抗体药物结合剂），其包含与抗原结合分子（如抗体）连接的这种新型细胞毒性肽；其中这种免疫结合剂可用于治疗细胞增殖性疾病。本发明进一步提供了包含这些免疫共轭物的药物组合物、包含这些免疫共轭物与治疗共用试剂的组合物，以及使用这些免疫共轭物和组合物治疗细胞增殖障碍的方法。
• Antibody conjugates comprising toll-like receptor agonist
  申请人：Cortez Alex

  公开号：US10973826B2

  公开（公告）日：2021-04-13

  Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

  本文提供了包含收费样受体激动剂的抗体共轭物，以及使用这种共轭物治疗癌症的方法。在某些实施方案中，共轭物包括抗 HER2 抗体。
• ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST
  申请人：NOVARTIS AG

  公开号：US20210346387A1

  公开（公告）日：2021-11-11

  Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.
• ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF
  申请人：Magenta Therapeutics, Inc.

  公开号：US20210371524A1

  公开（公告）日：2021-12-02

  Disclosed are anti-CD45 antibodies and antibody drug conjugates (ADCs) useful in therapeutic methods, including targeting CD45 expressing hematopoietic stem cells (HSCs) or immune cells prior to transplantation.
• CONDITIONING METHODS FOR GENE THERAPY
  申请人：Magenta Therapeutics, Inc.

  公开号：US20220175946A1

  公开（公告）日：2022-06-09

  The disclosure provides compositions and methods useful for the depletion of a specific population of endogenous hematopoietic stem cells and/or immune cells from a subject prior to transplantation with genetically modified stem cells to improve the engraftment of the transplanted stem cells and provide gene therapy. The disclosure provides compositions and methods for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ or CD45+ cells in a patient, such as a human.